NOT FOR DISTRIBUTION
Header cover image

Market Cap

Rp2.6t

Last Updated

2021/05/10 17:33 UTC

Data Sources

Company Financials

Executive Summary

PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia and internationally. More Details


Snowflake Analysis

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has Darya-Varia Laboratoria's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DVLA is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: DVLA's weekly volatility (2%) has been stable over the past year.


Market Performance


7 Day Return

0%

DVLA

1.3%

ID Pharmaceuticals

-0.5%

ID Market


1 Year Return

8.8%

DVLA

20.4%

ID Pharmaceuticals

22.3%

ID Market

Return vs Industry: DVLA underperformed the ID Pharmaceuticals industry which returned 20.4% over the past year.

Return vs Market: DVLA underperformed the ID Market which returned 22.3% over the past year.


Shareholder returns

DVLAIndustryMarket
7 Day0%1.3%-0.5%
30 Day-2.1%-3.8%-2.7%
90 Day-0.8%-9.1%-5.5%
1 Year13.9%8.8%22.7%20.4%26.3%22.3%
3 Year39.6%20.2%2.3%-3.3%2.3%-5.4%
5 Year95.7%56.7%32.9%20.3%34.1%17.8%

Long-Term Price Volatility Vs. Market

How volatile is Darya-Varia Laboratoria's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Darya-Varia Laboratoria undervalued compared to its fair value and its price relative to the market?

13.75x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: DVLA (IDR2350) is trading above our estimate of fair value (IDR1796.97)

Significantly Below Fair Value: DVLA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DVLA is good value based on its PE Ratio (13.7x) compared to the ID Pharmaceuticals industry average (25x).

PE vs Market: DVLA is good value based on its PE Ratio (13.7x) compared to the ID market (22.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DVLA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DVLA is good value based on its PB Ratio (1.9x) compared to the ID Pharmaceuticals industry average (2.4x).


Future Growth

How is Darya-Varia Laboratoria forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Darya-Varia Laboratoria has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Darya-Varia Laboratoria performed over the past 5 years?

13.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DVLA has high quality earnings.

Growing Profit Margin: DVLA's current net profit margins (11.4%) are lower than last year (11.5%).


Past Earnings Growth Analysis

Earnings Trend: DVLA's earnings have grown by 13.5% per year over the past 5 years.

Accelerating Growth: DVLA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DVLA had negative earnings growth (-11%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9%).


Return on Equity

High ROE: DVLA's Return on Equity (14.1%) is considered low.


Financial Health

How is Darya-Varia Laboratoria's financial position?


Financial Position Analysis

Short Term Liabilities: DVLA's short term assets (IDR1,364.4B) exceed its short term liabilities (IDR419.8B).

Long Term Liabilities: DVLA's short term assets (IDR1,364.4B) exceed its long term liabilities (IDR133.7B).


Debt to Equity History and Analysis

Debt Level: DVLA is debt free.

Reducing Debt: DVLA has not had any debt for past 5 years.

Debt Coverage: DVLA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: DVLA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Darya-Varia Laboratoria current dividend yield, its reliability and sustainability?

4.55%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: DVLA's dividend (4.55%) is higher than the bottom 25% of dividend payers in the ID market (1.15%).

High Dividend: DVLA's dividend (4.55%) is low compared to the top 25% of dividend payers in the ID market (4.83%).


Stability and Growth of Payments

Stable Dividend: DVLA's dividend payments have been volatile in the past 10 years.

Growing Dividend: DVLA's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (40.9%), DVLA's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Jose Romana (58 yo)

0.58

Tenure

Mr. Jose Sumpaico Romana serves as President Director at PT Darya-Varia Laboratoria Tbk since October 2020. Mr. Romana served as Vice President Director and Director at PT Darya-Varia Laboratoria Tbk since...


Leadership Team

Experienced Management: DVLA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: DVLA's board of directors are considered experienced (7.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PT Darya-Varia Laboratoria Tbk's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PT Darya-Varia Laboratoria Tbk
  • Ticker: DVLA
  • Exchange: IDX
  • Founded: 1976
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: Rp2.632t
  • Shares outstanding: 1.12b
  • Website: https://www.darya-varia.com

Number of Employees


Location

  • PT Darya-Varia Laboratoria Tbk
  • Tower C
  • South Quarter
  • Jakarta
  • Jakarta Raya
  • 12430
  • Indonesia

Listings


Biography

PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia and internationally. It operates in three segments: Prescription Drugs, Consumer ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/10 17:33
End of Day Share Price2021/05/10 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.